CRTX vs. ACHL, INAB, INKT, TARA, CYTH, SRZN, WINT, BCLI, ESLA, and PLUR
Should you be buying Cortexyme stock or one of its competitors? The main competitors of Cortexyme include Achilles Therapeutics (ACHL), IN8bio (INAB), MiNK Therapeutics (INKT), Protara Therapeutics (TARA), Cyclo Therapeutics (CYTH), Surrozen (SRZN), Windtree Therapeutics (WINT), Brainstorm Cell Therapeutics (BCLI), Estrella Immunopharma (ESLA), and Pluri (PLUR). These companies are all part of the "medical" sector.
Cortexyme (NASDAQ:CRTX) and Achilles Therapeutics (NASDAQ:ACHL) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and community ranking.
Cortexyme has a beta of 1.4, meaning that its stock price is 40% more volatile than the S&P 500. Comparatively, Achilles Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
63.2% of Cortexyme shares are owned by institutional investors. Comparatively, 56.4% of Achilles Therapeutics shares are owned by institutional investors. 27.9% of Cortexyme shares are owned by insiders. Comparatively, 5.4% of Achilles Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Achilles Therapeutics had 3 more articles in the media than Cortexyme. MarketBeat recorded 3 mentions for Achilles Therapeutics and 0 mentions for Cortexyme. Cortexyme's average media sentiment score of 0.00 equaled Achilles Therapeutics'average media sentiment score.
Cortexyme received 137 more outperform votes than Achilles Therapeutics when rated by MarketBeat users. Likewise, 64.44% of users gave Cortexyme an outperform vote while only 54.84% of users gave Achilles Therapeutics an outperform vote.
Achilles Therapeutics is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.
Achilles Therapeutics has a consensus target price of $4.00, indicating a potential upside of 416.53%. Given Achilles Therapeutics' higher probable upside, analysts plainly believe Achilles Therapeutics is more favorable than Cortexyme.
Achilles Therapeutics' return on equity of -42.55% beat Cortexyme's return on equity.
Summary
Achilles Therapeutics beats Cortexyme on 7 of the 13 factors compared between the two stocks.
Get Cortexyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cortexyme Competitors List
Related Companies and Tools
